National costs associated with methicillin-susceptible and methicillin-resistant staphylococcus aureus hospitalizations in the United States, 2010-2014

Clinical Infectious Diseases

Volumn 68, Issue 1, 2019, Pages 22-28

  Klein, Eili Y ^a,c   Jiang, Wendi ^c   Mojica, Nestor ^c   Tseng, Katie K ^c   McNeill, Ryan ^d,e   Cosgrove, Sara E ^a,b   Perl, Trish M ^f  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Economics and Policy   (United States)

^d Reuters New Media Inc   (United States)

^e CITY UNIVERSITY OF NEW YORK   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

antimicrobial resistance; excess cost of resistant infections; hospitalization costs; national inpatient sample; propensity score adjusted costs

Indexed keywords

ADULT; AGED; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HOSPITAL INFECTION; HOSPITAL MORTALITY; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY RATE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; REVIEW; SEPTICEMIA; STAPHYLOCOCCAL PNEUMONIA; UNITED STATES; DRUG EFFECT; ECONOMICS; HOSPITALIZATION; ISOLATION AND PURIFICATION; METHICILLIN RESISTANCE; MIDDLE AGED; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADULT; AGED; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; METHICILLIN RESISTANCE; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 85051044475     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy399     Document Type: Review

References (25)

1. Patricia Jevons M. "Celbenin"-resistant staphylococci. Br Med J 1961; 1:124-5.
2. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961; 14:385-93.
3. US Department of Health and Human Services. Antibiotic resistance threats in the United States, 2013. Atlanta, GA, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013. Accessed 31 May 2014.
4. Klein EY, Sun L, Smith DL, Laxminarayan R. The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: A national observational study. Am J Epidemiol 2013; 177:666-74.
5. Klein EY, Mojica N, Jiang W, et al., Trends in methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin Infect Dis 2017; 65:1921-3.
6. Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: Review and analysis of the literature. Pharmacoeconomics 2007; 25:751-68.
7. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-74.
8. Filice GA, Nyman JA, Lexau C, et al., Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 2010; 31:365-73.
9. Reed SD, Friedman JY, Engemann JJ, et al., Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26:175-83.
10. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999; 5:9-17.
11. Engemann JJ, Carmeli Y, Cosgrove SE, et al., Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36:592-8.
12. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004; 25:425-30.
13. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52:113-22.
14. Stewardson AJ, Allignol A, Beyersmann J, et al., The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Euro Surveill 2016; 21:pii=30319. Available at: http://www.eurosurveillance.org/ViewArticle.aspxArticleId=22559. Accessed 18 August 2017.
15. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection Infect Control Hosp Epidemiol 2009; 30:453-60.
16. Houchens R, Ross D, Elixhauser A, Jiang J. Nationwide inpatient sample (NIS) redesign final report. Rockville, MD: US Agency for Healthcare Research and Quality, 2014. Available at: http://www.hcup-us.ahrq.gov/reports/methods/methods.jsp. Accessed 12 July 2017.
17. Cost-to-charge ratio files: User guide for National Inpatient Sample (NIS) CCRs. Rockville, MD: US Agency for Healthcare Research and Quality, 2017. Available at: https://www.hcup-us.ahrq.gov/db/state/CCR-NIS-UserGuide-2001-2015. pdf. Accessed 12 July 2017.
18. Dugoff EH, Schuler M, Stuart EA. Generalizing observational study results: Applying propensity score methods to complex surveys. Health Serv Res 2014; 49:284-303.
19. Quan H, Sundararajan V, Halfon P, et al., Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43:1130-9.
20. May L, Klein EY, Martinez EM, Mojica N, Miller LG. Incidence and factors associated with emergency department visits for recurrent skin and soft tissue infections in patients in California, 2005-2011. Epidemiol Infect 2017; 145:746-54.
21. David MZ, Boyle-Vavra S, Zychowski DL, Daum RS. Methicillin-susceptible Staphylococcus aureus as a predominantly healthcare-associated pathogen: A possible reversal of roles PLoS One 2011; 6:e18217.
22. McDanel JS, Perencevich EN, Diekema DJ, et al., Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis 2015; 61:361-7.
23. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36:53-9.
24. Schaefer MK, Ellingson K, Conover C, et al., Evaluation of International Classification of Diseases, Ninth Revision, Clinical Modification codes for reporting methicillin-resistant Staphylococcus aureus infections at a hospital in Illinois. Infect Control Hosp Epidemiol 2010; 31:463-8.
25. Goto M, Ohl ME, Schweizer ML, Perencevich EN. Accuracy of administrative code data for the surveillance of healthcare-associated infections: A systematic review and meta-analysis. Clin Infect Dis 2014; 58:688-96.